X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/pharmabcine-receives-ind-approval-from-the-korean-mfds-for-phase-i-clinical-trial-of-its-novel-tie2-agonistic-antibody-in-namd-301831855.html
https://www.prnewswire.com/news-releases/pharmabcine-to-participate-in-bio-international-convention-2023-301817983.html
https://www.prnewswire.com/news-releases/pharmabcine-announces-collaboration-agreement-with-msd-to-evaluate-anti-vista-antibody-pmc-309-in-combination-with-keytruda-pembrolizumab-301699915.html
https://www.prnewswire.com/news-releases/pharmabcine-to-participate-in-bio-europe-2022-301632759.html
https://www.biospectrumasia.com/news/26/20177/pharmabcine-announces-positive-results-for-its-novel-tie2-activating-antibody-in-glp-toxicology-study.html
https://www.prnewswire.com/news-releases/pharmabcine-presents-updated-preclinical-data-of-its-anti-vista-antibody-candidate-at-aacr-2022-301522480.html
https://www.prnewswire.com/news-releases/rnagene-signs-a-collaborative-research-agreement-with-pharmabcine-to-develop-novel-mrna-therapeutics-301506308.html
https://www.biospectrumasia.com/news/26/19855/south-korea-lays-focus-on-novel-mrna-therapeutics.html
https://www.biospace.com/article/releases/pharmabcine-announces-patent-grant-in-australia-for-its-anti-vista-antibody/?s=71
https://www.prnewswire.com/news-releases/pharmabcine-receives-hrec-clearance-for-phase-ii-trial-of-olinvacimab-and-pembrolizumab-in-mtnbc-301368208.html
Market Place
Share 
